ArticleNanotoxicology
Lipidomics analysis reveals signature inflammatory and specialized pro-resolving mediators at the junction of inflammation-resolution transition in mouse lungs exposed to multiwalled carbon nanotubes.
Article in Nanotoxicology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pulmonary exposure to certain multiwalled carbon nanotubes (MWCNTs) triggers significant inflammation that is regulated temporally by powerful mediators of inflammation and resolution. Among these mediators, inflammatory lipid mediators (ILMs) and specialized pro-resolving mediators (SPMs) have garnered increasing attention. In this study, lipidomics analysis revealed that fibrogenic MWCNTs stimulate the production of signature ILMs and SPMs in mouse lungs, marking a phenotypic shift from acute inflammation to resolution. Mice exposed to 40 μg MWCNTs via oropharyngeal aspiration exhibited dynamic, polarized pulmonary inflammation. By day 7 post-exposure, lung tissue showed elevated M2 macrophage markers and cytokines, with lesions characterized by moderate neutrophil infiltration and a marked increase in macrophages within alveolar sacs and interstitial spaces. These macrophages contained engulfed nanoparticles and formed clusters of varying sizes. In vitro, MWCNTs promoted nanoparticle phagocytosis and cytoplasmic phospholipid accumulation. Lipidomics profiling of lung bioactive lipids, performed using ultraperformance liquid chromatography-tandem mass spectrometry, showed significant increases in ILMs and SPMs. These included prostaglandin (PG) E2, PGD2, thromboxane B2, leukotriene B4, and lipoxin B4 from the arachidonic acid pathway; resolvin (Rv) D5, protectin DX, maresin 1, 17-hydroxydocosahexaenoic acid (HDHA), and 14S-HDHA from the docosahexaenoic acid pathway; and RvE2, 15-hydroxyeicosapentaenoic acid (HEPE), and 18-HEPE from the eicosapentaenoic acid pathway. These findings suggest that MWCNTs trigger a distinct lipid mediator signature at the junction of inflammation-resolution transition to promote the programmatic switch from acute inflammation to resolution, supporting continued particle clearance, inflammation resolution, and return to homeostasis in response to nanoparticle exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.